Zhang Qian

zhqcindy@163.com

MGI, a subsidiary of BGI Group, introduced its newest model genetic sequencer, MGISEQ-T7, which provides vast improvements in speed, throughput and flexibility, at the 13th International Conference on Genomics (ICG-13), opened in Shenzhen on Thursday.

The new sequencer is built with innovative quadruple flowcell staging that allows simultaneous but independent operation of one to four flowcells in a single run. The MGI proprietary technology used in the new sequencer ensures higher accuracy and improves efficiency through upgrades to the flowcell, fluid, and biochemical and optical system.

A supercomputer for the life science industry, MGISEQ-T7 takes the production capacity of the sequencer to a new level with daily output of up to 6 terabytes of data.

Wang Jian, president of BGI Group, said Thursday that the research on the human genome and related applications will serve all human beings around the world. “The mission of MGI is to help people live better and healthier lives, which is always the core concept of BGI Group.”

“MGI is developing at an unprecedented speed, and our technology has advanced to lead the market,” said MGI’s CEO Mu Feng. “This new instrument demonstrates the level of MGI’s innovation and commitment to progress: We continually challenge ourselves to drive towards our goal of making highly accurate next-generation sequencing more affordable to benefit more people around the world.”

Mu said the quad-flowcell platform enables multiple flowcells with different read lengths and applications to be processed independently at any time in a single run, resulting in greater savings in time and cost.